Neumora Therapeutics to Participate in Upcoming Conferences in September

Rhea-AI Summary

Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, has announced its participation in three major investor conferences in September 2025. The company, which focuses on developing therapeutics for prevalent diseases through seven distinct programs, will attend the Wells Fargo Healthcare Conference (Sept. 4), Morgan Stanley Global Healthcare Conference (Sept. 8), and H.C. Wainwright Global Investment Conference (Sept. 9).

Management will be available for one-on-one meetings at the Wells Fargo and Morgan Stanley events, while participating in a fireside chat at the H.C. Wainwright conference. The fireside chat will be webcast live and archived for 30 days on the company's website.

WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in three investor conferences in September.

• 2025 Wells Fargo Healthcare Conference: Members of management will be available for one-on-one meetings on Thursday, September 4, 2025, in Boston, MA.
• Morgan Stanley 23^rd Annual Global Healthcare Conference: Members of management will be available for one-on-one meetings on Monday, September 8, 2025, in New York, NY.
• H.C. Wainwright 27^th Annual Global Investment Conference: Members of management will participate in a fireside chat on Tuesday, September 9, 2025, at 1:00 p.m. ET in New York, NY.
  

A live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com

FAQ

When is Neumora Therapeutics (NMRA) presenting at the H.C. Wainwright Conference?

Neumora Therapeutics will participate in a fireside chat on Tuesday, September 9, 2025, at 1:00 p.m. ET in New York, NY.

How can investors access Neumora's H.C. Wainwright Conference presentation?

Investors can access the live webcast through the events and presentations section of Neumora's website at www.neumoratx.com. A replay will be available for up to 30 days.

What conferences is Neumora Therapeutics (NMRA) attending in September 2025?

Neumora is attending three conferences: the Wells Fargo Healthcare Conference (Sept. 4), Morgan Stanley Global Healthcare Conference (Sept. 8), and H.C. Wainwright Global Investment Conference (Sept. 9).

How many therapeutic programs does Neumora Therapeutics have in development?

Neumora Therapeutics has seven programs in their therapeutic pipeline, targeting novel mechanisms of action for underserved, prevalent diseases.